{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:40:18Z","timestamp":1793342418180,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.eururo.2013.10.032","type":"journal-article","created":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T20:15:46Z","timestamp":1383336946000},"page":"565-573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":290,"title":["Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist"],"prefix":"10.1016","volume":"65","author":[{"given":"Peter C.","family":"Albertsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Grady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine K.","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2013.10.032_bib0005","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","article-title":"Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions","volume":"25","author":"D\u2019Amico","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2013.10.032_bib0010","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keeting","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2013.10.032_bib0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2012.523","article-title":"Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?","volume":"108","author":"Bourke","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2013.10.032_bib0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2012.09.008","article-title":"The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy","volume":"86","author":"Conteduca","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eururo.2013.10.032_bib0025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.299.3.289","article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial","volume":"299","author":"D\u2019Amico","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2013.10.032_bib0030","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","article-title":"Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction","volume":"302","author":"Nanda","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2013.10.032_bib0035","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2013.10.032_bib0040","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and the American Urological Association: endorsed by the American Society of Radiation Oncology","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.eururo.2013.10.032_bib0045","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ecl.2011.05.005","article-title":"The timing and extent of androgen deprivation therapy for prostate cancer: weighing the clinical evidence","volume":"40","author":"Ginzburg","year":"2011","journal-title":"Endocrinol Metab Clin N Am"},{"key":"10.1016\/j.eururo.2013.10.032_bib0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eururo.2011.08.026","article-title":"Contemporary role of androgen deprivation therapy for prostate cancer","volume":"61","author":"Pagliarulo","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.10.032_bib0055","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.critrevonc.2008.09.004","article-title":"Management of complications of androgen deprivation therapy in older man","volume":"70","author":"Mohile","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eururo.2013.10.032_bib0060","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1210\/jc.2011-1137","article-title":"Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis","volume":"96","author":"Araujo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2013.10.032_bib0065","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1530\/EJE-11-0447","article-title":"Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study","volume":"165","author":"Corona","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eururo.2013.10.032_bib0070","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1530\/JOE-12-0455","article-title":"Testosterone: a metabolic hormone in health and disease","volume":"217","author":"Kelly","year":"2013","journal-title":"J Endocrinol"},{"key":"10.1016\/j.eururo.2013.10.032_bib0075","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2013.10.032_bib0080","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2013.10.032_bib0085","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/01.CIR.92.3.657","article-title":"Coronary plaque disruption","volume":"92","author":"Falk","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.eururo.2013.10.032_bib0090","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1161\/CIRCULATIONAHA.105.537878","article-title":"Pathophysiology of coronary artery disease","volume":"111","author":"Libby","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.eururo.2013.10.032_bib0095","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/01.CIR.0000087480.94275.97","article-title":"From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I","volume":"108","author":"Naghavi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.eururo.2013.10.032_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9149(89)90242-7","article-title":"Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes","volume":"63","author":"Falk","year":"1989","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.eururo.2013.10.032_bib0105","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1136\/hrt.2004.041798","article-title":"Pathologic assessment of the vulnerable human coronary plaque","volume":"90","author":"Kolodgie","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.eururo.2013.10.032_bib0110","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1161\/01.CIR.89.1.36","article-title":"Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology","volume":"89","author":"Van der Wal","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.eururo.2013.10.032_bib0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0021-9150(99)00011-8","article-title":"Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines","volume":"145","author":"Frostegard","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.eururo.2013.10.032_bib0120","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ni.2001","article-title":"The immune system in atherosclerosis","volume":"12","author":"Hansson","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.eururo.2013.10.032_bib0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1172\/JCI63108","article-title":"Adaptive immunity in atherogenesis: new insights and therapeutic approaches","volume":"123","author":"Lichtman","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2013.10.032_bib0130","first-page":"743","article-title":"Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro","volume":"84","author":"Chen","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2013.10.032_bib0135","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2249.2005.02904.x","article-title":"GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mrna expression in healthy males","volume":"142","author":"Tanriverdi","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.eururo.2013.10.032_bib0140","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1095\/biolreprod.102.012211","article-title":"Gonadotropin-releasing hormone alters the t helper cytokine balance in the pregnant rat","volume":"68","author":"Dixit","year":"2003","journal-title":"Biol Reprod"},{"key":"10.1016\/j.eururo.2013.10.032_bib0145","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1001283","article-title":"Expression of follicle-stimulating hormone receptor in tumor blood vessels","volume":"363","author":"Radu","year":"2010","journal-title":"N Eng J Med"},{"key":"10.1016\/j.eururo.2013.10.032_bib0150","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1161\/CIRCULATIONAHA.109.865840","article-title":"Cardiovascular and overall mortality risk in relation to alcohol consumption in patients with cardiovascular disease","volume":"121","author":"Costanzo","year":"2010","journal-title":"Circulation"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813011081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813011081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:03:28Z","timestamp":1759583008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283813011081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0302283813011081"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2013.10.032","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2013.10.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}